RECOGNIZE-I: Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I

Sponsor
Ruijin Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05884008
Collaborator
(none)
300
9
32
33.3
1

Study Details

Study Description

Brief Summary

This study is a multicenter, retrospective imaging study. The study intends to retrospectively enroll patients with acute myocardial infarction who had received coronary CTA in a certain time-window before this event. All coronary CTA will be analyzed by anatomic, functional and radiomic analysis, assisted by artificial intelligence. The purpose of this study is to establish a coronary artery disease risk stratification system by coronary CTA.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Coronary angiography has been the gold standard for the diagnosis of coronary heart disease and PCI decision-making. However, the value of CAG in risk stratification is limited due to its invasive nature and lack of ability to evaluate coronary physiology and plaque characteristics, which often leads to over-treatment or under-treatment. In recent years, with the development and improvement of imaging technology, the resolution and diagnostic accuracy of coronary artery CTA have been greatly improved, and the subsequent anatomy and function (non-invasive CT-FFR, etc.) have made the assessment of coronary artery lesion risk multi-dimensional. Comprehensive and accurate coronary artery CTA scan plays a positive role in establishing the appropriate standard for PCI and improving the prognosis of patients. However, the existing problems of coronary artery CTA are insufficient imaging studies, complex image analysis, inconsistent diagnostic criteria, and insufficient clinical evidence. This study is one of the series of clinical studies on the topic of "Risk Evaluation by COronary Computed Tomography and Artificial Intelligence Based fuNctIonal analyZing tEchniques (RECOGNIZE)". The purpose of the study is to establish a coronary artery disease risk stratification system by coronary CTA and anatomic, functional and radiomic analysis, assisted by artificial intelligence.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Coronary Computed Tomography Angiography and Functional Analysis in Risk Stratification of Coronary Artery Disease: A Retrospective Cohort Study
    Actual Study Start Date :
    May 1, 2023
    Anticipated Primary Completion Date :
    Jun 30, 2025
    Anticipated Study Completion Date :
    Dec 31, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Coronary artery plaque risk level [3 months to 5 years prior to acute myocardial infarction]

      Coronary plaque risk was determined using an artificial intelligence (AI) guided risk stratification model based on Coronary CTA structural, functional and radiomic analysis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age between 18-80 years old

    • Received coronary CT angiography 3 months to 5 years prior to acute coronary myocardial infarction. CCTA identified coronary atherosclerotic plaques with diameter stenosis ≥ 10%

    Exclusion Criteria:
    • Familial hypercholesterolemia

    • Prior history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)

    • Prior history of myocardial infarction before the recent event

    • Severe liver or renal insufficiency

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cangzhou Center Hospital Cangzhou Hebei China
    2 First affiliated hospital of Harbin Medical University Harbin Heilongjiang China
    3 First affiliated hospital of Zhengzhou University Zhengzhou Henan China
    4 Union Hospital, Tongji Medical College, Huazhong University of Science and Techonology Wuhan Hubei China
    5 First Hospital of Nanjing Nanjing Jiangsu China
    6 First affiliated hospital of Dalian Medical College Dalian Liaoning China
    7 General Hospital of Northern Theater Command Shenyang Liaoning China
    8 Ruijin Hospital, Shanghai Jiaotong University School of Medicine Shanghai Shanghai China 200025
    9 Xinhua Hospital, Shanghai Jiaotong University School of Medicine Shanghai Shanghai China

    Sponsors and Collaborators

    • Ruijin Hospital

    Investigators

    • Principal Investigator: Ruiyan Zhang, M.D., Ph.D., Ruijin Hospital
    • Study Chair: Lin Lu, M.D., Ph.D., Ruijin Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    RUIYAN ZHANG, Director of Cardiology Department, Principal Investigator, Ruijin Hospital
    ClinicalTrials.gov Identifier:
    NCT05884008
    Other Study ID Numbers:
    • 2022YFC2533502-1
    First Posted:
    Jun 1, 2023
    Last Update Posted:
    Jun 1, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by RUIYAN ZHANG, Director of Cardiology Department, Principal Investigator, Ruijin Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 1, 2023